# A Multicenter Phase II Trial to Evaluate Rechallenge With Platinum-based Chemotherapy (Carboplatin, Etoposide) for Progression During Tarlatamab Therapy in Relapsed Extensive Disease Small-cell Lung Cancer (SCLC)

> **NCT07699237** · PHASE2 · NOT_YET_RECRUITING · sponsor: **University of Cologne** · enrollment: 54 (estimated)

## Conditions studied

- Extensive Disease Small Cell Lung Cancer

## Interventions

- **DRUG:** Tarlatamab, Carboplatin, Etoposid

## Key facts

- **NCT ID:** NCT07699237
- **Lead sponsor:** University of Cologne
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-11-01
- **Primary completion:** 2031-06-30
- **Final completion:** 2031-06-30
- **Target enrollment:** 54 (ESTIMATED)
- **Last updated:** 2026-07-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07699237

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07699237, "A Multicenter Phase II Trial to Evaluate Rechallenge With Platinum-based Chemotherapy (Carboplatin, Etoposide) for Progression During Tarlatamab Therapy in Relapsed Extensive Disease Small-cell Lung Cancer (SCLC)". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07699237. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*